|
||||||||||||||
 |
||||||||||||||
|
|
New Research - January 2009Exhaled Nitric Oxide (ENO) as assessed during daily telemonitoring may not add to the benefit of monitoring symptomsThis group of investigators from the Netherlands assessed symptoms and exhaled nitric oxide via telemonitoring in a group of atopic asthmatic children. One hundred fifty-one children were randomly assigned to two groups. One group monitored symptoms only, and the other monitored symptoms and ENO. Symptoms were scored using an electronic diary daily over 30 weeks. Seventy-seven received a portable ENO analyzer. Data were transmitted each day to coordinating centers. In addition, telephone contact was made every three weeks. Corticosteroid dosing was monitored and modified according to daily ENO and symptoms. Visits to the clinic were also performed at weeks 3, 12, 21, and 30. The primary endpoint was the portion of symptom-free days in the last 12 study weeks. The authors found that telemonitoring was feasible, both for monitoring ENO and daily diary entries. In addition, both groups of children had an increase in symptom-free days, FEV1, and quality of life. Also both demonstrated a reduction in corticosteroid dose. Although there was a trend for fewer exacerbations in the ENO group, there were no statistically significant differences between the two groups in the primary endpoint or other measures. The authors concluded that daily telemonitoring improved asthma control while lowering corticosteroid dose. However, they found no added value by adding ENO to symptom monitoring. ReferenceJongste JC, et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine 2009; 179:93-97. |
||||||||||||
|
© 1996-2009 · All Rights Reserved · American Academy of Allergy Asthma & Immunology |
||||||||||||||
